Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9511)	1/30/2003 1:30:02 PM
From: Icebrg	Read Replies (1) \| Respond to of 9719

V! >>Spending at an alarming rate>> Some of this is tied to their R&D early cooperations and there is revenue to match. >>Obesity program a failure>> But was it in the stock price? >>$560m of debt coming due>> 600 actually. Yes, that is a concern. >>IMO Velcade has less than 50% chance of approval on phase II trial>> 80-90 % I would say. These were good results for patients who didn't have many other options. Considering ODAC voted in favor of Iressa, I can't see how or why they should turn down Velcade. >>Integrin is a good product but modest growth ahead.>> Yes, it will slow down. Velcade is the key for this year. In combination with how they will be handling their debt. Erik